Correction to: A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency | Synapse
March 3, 2026Open Access
Correction to: A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency
Puntos clave
Pharmacokinetics and efficacy are critical for effective immune globulin treatments in patients with primary immunodeficiency.
The correction enhances understanding of loading and maintenance dosing strategies in treatment-naïve and experienced patients.
Observational analysis of pharmacokinetics revealed variability in response among patients, impacting efficacy and safety profiles.
Highlighting refinements in dosing may improve treatment outcomes, necessitating further validation across diverse patient populations.